bezafibrate
2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid
Identification
| Name | bezafibrate |
| CAS Number | 41859-67-0 |
| EINECS | 255-567-9 |
| FDA UNII | Y9449Q51XH |
| Molecular Formula | C19 H20 Cl N O4 |
| Molecular Weight | 361.82420000 |
| MDL Number | MFCD00078970 |
| Nikkaji Number | J16.626J |
| Beilstein | 4267656 |
| XlogP3 | 3.80 (est) |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Melting Point | 186.00 °C. @ 760.00 mm Hg |
| Boiling Point | 572.10 °C. @ 760.00 mm Hg (est) |
| Flash Point | 572.00 °F. TCC ( 299.80 °C. ) (est) |
| logP (o/w) | 2.504 (est) |
| Soluble in | water, 1.224 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Preferred SDS | View |
| Oral/Parenteral Toxicity | oral-man TDLo 514 mg/kg/60D- |
| Dermal Toxicity | subcutaneous-mouse LD50 1635 mg/kg |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements', 'BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD\nLUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION\nBEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)']
Safety in Use
| Category | pharmaceuticals / chemical synthisis |
| Recommendation for bezafibrate usage levels up to | not for fragrance use. |
| Recommendation for bezafibrate flavor usage levels up to | not for flavor use. |
BOC Sciences
Best of Chemicals Supplier
Quality supplier of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecul...
Potential Uses
Natural Occurrence
Synonyms
azufibrat
befibrat
bezafibratum
bezalande
bezapuren
2-(p-(2-(p-
chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
2-[4-[2-(4-
chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid
2-[p-[2-(p-
chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid
2-[p-[2-p-
chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid
2-{4-[2-(4-
chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid
2-[4-[2-[(4-
chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid
2-[4-[2-[(4-
chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
2-(4-{2-[(4-
chlorophenyl)carbonylamino]ethyl}phenoxy)-2-methylpropanoic acid
difaterol
durabezur
propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-
propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-
propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-
reducterol
sklerofibrat
PubMed:
Irrigation of root vegetables with treated wastewater: evaluating uptake of pharmaceuticals and the associated human health risks.
PubMed:
Quantitative evaluation of initial symptoms as predictors to detect adverse drug reactions using Bayes' theory: expansion and evaluation of drug-adverse drug reaction-initial symptom combinations using adverse event reporting system database.
PubMed:
Biodegradability of pharmaceutical compounds in agricultural soils irrigated with treated wastewater.
PubMed:
Long-chain free fatty acid profiling analysis by liquid chromatography-mass spectrometry in mouse treated with peroxisome proliferator-activated receptor α agonist.
PubMed:
Melanocortin 4 receptor becomes an ACTH receptor by coexpression of melanocortin receptor accessory protein 2.
PubMed:
Dill seed extract improves abnormalities in lipid metabolism through peroxisome proliferator-activated receptor-α (PPAR-α) activation in diabetic obese mice.
PubMed:
Structural Features and Transcriptional Activity of Chicken PPARs (α, β, and γ).
PubMed:
Peroxisome proliferator-activated receptor α (PPARα) activation advances locomotor activity and feeding daily rhythms in mice.
PubMed:
Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio).
PubMed:
Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.
PubMed:
Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.
PubMed:
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
PubMed:
Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes.
PubMed:
Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling.
PubMed:
Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms.
PubMed:
Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.
PubMed:
Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
PubMed:
Differential effects of pyrazinamide and clofibrate on gene expression of rat hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme of the tryptophan-NAD pathway.
PubMed:
Ethanolamine modulates DNA synthesis through epidermal growth factor receptor in rat primary hepatocytes.
PubMed:
Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites.
PubMed:
Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
PubMed:
Hypertriglyceridemia: associated risks and effect of drug treatment.
PubMed:
Bezafibrate-induced anaphylactic shock: unusual clinical presentation.
PubMed:
Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.
PubMed:
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
PubMed:
Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth.
PubMed:
The patient at risk: who should we be treating?
PubMed:
The patient at risk: who should we be treating?
PubMed:
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
PubMed:
Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
PubMed:
The role of NADPH in the regulation of glucose-6-phosphate and 6-phosphogluconate dehydrogenases in rat adipose tissue.
PubMed:
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
PubMed:
Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment.